Other languages Akili, Inc.

Equities

AKLI

US00974B1070

End-of-day quote Nasdaq Other stock markets 23:00:00 07/05/2024 BST			5-day change	1st Jan Change
0.406 ^USD	-0.29%		+3.44%	-16.65%

04-30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
04-30	Akili, Inc. to Reduce Workforce	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	04-30
Akili, Inc. to Reduce Workforce	04-30
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	04-30
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29
Sector Update: Health Care Stocks Ease Late Afternoon	02-26
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	02-26
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	02-26
Akili Appoints John Spinale to the Board and Audit Committee	02-21
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	01-05
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board	12-20
Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration	12-18
Akili, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Top Premarket Decliners	26/10/23
Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce	12/10/23
Akili, Inc. Announces Executive Changes	06/10/23
Akili, Inc. Announces CEO Changes	06/10/23
Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd	21/09/23
Akili to Cut 40% of Workforce Amid Transition to Over-the-Counter Model	13/09/23
Akili, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Akili, Inc.

Equities

AKLI

US00974B1070

Other languages

Filters